Literature DB >> 16547657

[Efficiency potential in the pacemaker/implantable cardioverter defibrillator outpatient clinic].

A Bauer1, J Bauer, M Bauer, K Kelemen, F Voss, J Senges-Becker, S Weretka, H A Katus, R Becker.   

Abstract

The aim of the present study was to elucidate whether the duration of a technical follow-up (FU) of a pacemaker (PM)/implantable cardioverter defibrillator (ICD) has an impact on cost-effectiveness in the outpatient clinic. We determined the time required for a complete FU of devices from three different manufacturers. In 130 patients (70 VVI/DDD-PM, 60 VVI/DDD-ICD) with either a PM (Phylos, Chorum/Talent, Kappa, EnPulse) or an ICD (Belos, Alto or GEM) the time was recorded for a complete FU including determination of lead impedance, sensing and pacing threshold. The time for activation of individual menue buttons was excluded. On the basis of time required for FU, cost-units (CU) were calculated for 2000 FU/year and for a presumed device longevity (PM 7 years, ICD 5 years). For VVI-PM, the duration of FU was almost identical for devices from different manufacturers (105+/-11 s to 125+/-8 s; p=n.s.). However, analysis of DDD-PM revealed marked differences (140+/-25 s vs 282+/-23 s, p<0.05). Time for FU of ICDs varied between 108+/-5 s and 207+/-21 s (p<0.05) in VVI-ICDs and between 129+/-8 ms and 225+/-23 s (p<0.05) in DDD-ICDs. The total savings could be 55 000 CU in VVI- and 53 333 CU in DDD-ICDs. For full automatic DDD-pacemakers (EnPulse) time for FU could be reduced to 58+/-3 s (p<0.05). Differences in FU times were caused by problems with telemetry, delay during booting of the programmer, interrogation at the beginning and at the end of FU and for sensing tests. Improving not only programmers and devices but also test automaticity could significantly increase cost-efficiency in the outpatient clinic.

Entities:  

Mesh:

Year:  2006        PMID: 16547657     DOI: 10.1007/s00399-006-0504-2

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  14 in total

Review 1.  Consensus statement on indications, guidelines for use, and recommendations for follow-up of implantable cardioverter defibrillators. North American Society of Electrophysiology and Pacing.

Authors:  S L Winters; D L Packer; F E Marchlinski; R Lazzara; D S Cannom; G E Breithardt; D A Wilber; A J Camm; J N Ruskin
Journal:  Pacing Clin Electrophysiol       Date:  2001-02       Impact factor: 1.976

2.  ["Activity based costing" in radiology].

Authors:  K J Klose; J Böttcher
Journal:  Radiologe       Date:  2002-05       Impact factor: 0.635

3.  Usability assessment of pacemaker programmers.

Authors:  Christine C Chiu; Kim J Vicente; Ilan Buffo-Sequeira; Robert M Hamilton; Brian W McCrindle
Journal:  Pacing Clin Electrophysiol       Date:  2004-10       Impact factor: 1.976

4.  Reprogramming pacemakers enhances longevity and is cost-effective.

Authors:  G H Crossley; D D Gayle; T W Simmons; W K Haisty; J R Bailey; K Davis-O'Brien; J W Hammon; D M Fitzgerald
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

5.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

Review 6.  Guidelines for pacemaker follow-up in Canada: a consensus statement of the Canadian Working Group on Cardiac Pacing.

Authors:  J D Fraser; A M Gillis; M E Irwin; S Nishimura; G F Tyers; F Philippon
Journal:  Can J Cardiol       Date:  2000-03       Impact factor: 5.223

7.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

8.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

9.  Cost-effectiveness of dual-chamber pacemaker therapy: does single lead VDD pacing reduce treatment costs of atrioventricular block?

Authors:  U K Wiegand; J Potratz; F Bode; R Schreiber; H Bonnemeier; W Peters; H A Katus
Journal:  Eur Heart J       Date:  2001-01       Impact factor: 29.983

Review 10.  Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence.

Authors:  Larry D Lynd; Bernie J O'Brien
Journal:  J Cardiovasc Electrophysiol       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.